Contact us
Apr 17, 2023

HANCHORBIO ANNOUNCES US IND CLEARANCE FOR THE MULTI-REGIONAL CLINICAL TRIAL OF HCB101 TO TREAT SOLID AND HEMATOLOGICAL MALIGNANCIES

Apr 13, 2023
HanchorBio Completes the Face-to-Face Scientific Advisory Board Meeting
HanchorBio Inc. completed a face-to-face Scientific Advisory Board (SAB) meeting on March 29, 2023, in Taipei, Taiwan withworld-renowned professors and few Board of Director (BOD) members.
Apr 25, 2023
about HanchorBio Q&A
1.Why was HanchorBio founded? 2.When was HanchorBio established, and what is its founding mission?3. What research achievements or fundraising successes has HanchorBio accomplished so far? 4.What is HanchorBio’s vision? 5.In the fields of biotechnology and healthcare, what contributions can HanchorBio make to society? 6.What are the key differences and advantages between HanchorBio’s drug candidates and traditional therapies? What is the core technology? 7.What is FBDB™? What makes it special, and how does it support research and development? 8.What is the expected scale or extent of the beneficiaries? For such multi-target biologics designed to reactivate the immune system against diseases, can this mechanism be applied to other diseases or medical fields?